Zealand Pharma revenue and financials
In the fiscal year ended December 2025, Zealand Pharma reported revenue of kr 9.21B (+14,598.86% year over year). Net income was kr 6.46B, a net margin of 70.0%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +14,598.86%
- 2025 vs 2024
- Net margin
- 70.0%
- 2024: -1,720.9%
How Zealand Pharma is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 116.9% a year on average over the last 5 years
Compound annual growth rate: from kr 192M in 2020 to kr 9.21B in 2025.
Operating margin rose from −785.3% to 75.1%
Operating income over revenue, 2022 → 2025: 860.4 percentage points.
Profits turn into cash: free cash flow equal to 110% of net income
Totals for fiscal years 2023–2025: free cash flow kr 5.12B, net income kr 4.67B.
Shares outstanding up 86.5% in 5 years
Average diluted shares, 2020 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Profitable in 1 of 5 fiscal years
Positive net income, fiscal years 2021–2025.
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9,215 | 62.7 | 343 | 104 | 109 | 192 | 41.3 | 38.0 | 136 | 231 |
| Cost of revenue | 0.8 | 7.9 | 3.2 | 0.0 | 11.0 | — | 0.4 | 3.4 | 14.2 | 30.9 |
| Gross profit | 9,214 | 54.8 | 340 | 104 | 97.6 | 192 | 40.9 | 34.6 | 122 | 200 |
| Selling, general and administrative | 496 | 404 | 216 | 258 | 298 | 222 | 67.9 | 43.5 | 47.3 | 58.6 |
| Research and development | 1,605 | 920 | 685 | 614 | 582 | 596 | 561 | 438 | 324 | 262 |
| Operating income | 6,917 | -1,269 | -561 | -817 | -782 | -626 | -588 | -447 | -249 | -119 |
| EBIT | 6,917 | -1,269 | -561 | -817 | -782 | -626 | -588 | -447 | -249 | -119 |
| EBITDA | 6,927 | -1,258 | -555 | -730 | -769 | -584 | -574 | -442 | -244 | -114 |
| Interest expense | 29.1 | 34.0 | 25.8 | 57.8 | 4.1 | 49.3 | 3.2 | 33.4 | 24.7 | 40.5 |
| Pre-tax income | 7,001 | -1,083 | -709 | -972 | -759 | -674 | -577 | 625 | -280 | -163 |
| Income tax | 546 | -4.6 | -5.1 | -6.4 | -3.9 | -4.8 | -5.1 | 43.8 | -5.5 | -5.5 |
| Net income | 6,455 | -1,079 | -704 | -1,202 | -1,018 | -847 | -572 | 581 | -274 | -157 |
| Net income to common shareholders | 6,455 | -1,079 | -704 | -966 | -755 | -669 | -572 | 581 | -274 | -157 |
| Basic EPS | 91.56 | -16.24 | -12.44 | -20.90 | -17.61 | -17.43 | -16.91 | 18.94 | -9.85 | -6.47 |
| Diluted EPS | 90.22 | -16.24 | -12.44 | -20.90 | -17.61 | -17.43 | -16.91 | 18.94 | -9.85 | -6.47 |
| Average shares (basic) | 70.5 | 66.4 | 56.6 | 46.2 | 42.9 | 38.4 | 33.8 | 30.7 | 27.9 | 24.3 |
| Average shares (diluted) | 71.5 | 66.4 | 56.6 | 46.2 | 42.9 | 38.4 | 33.8 | 30.7 | 27.9 | 24.3 |
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 4,491 | 34.0 | 68.9 | 49.6 | 9,088 | 8.0 | 9.1 | 4.4 | 34.1 | 15.1 | 23.2 | 296 |
| Cost of revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | 0.4 | -6.6 | 9.5 | 4.6 | 11.8 | 5.2 |
| Gross profit | 4,491 | 34.0 | 68.9 | 49.6 | 9,088 | 8.0 | 8.6 | 11.0 | 24.6 | 10.5 | 11.5 | 290 |
| Selling, general and administrative | 116 | 104 | 91.8 | 191 | 111 | 102 | 154 | 93.8 | 80.8 | 75.4 | 63.7 | 49.7 |
| Research and development | 516 | 469 | 530 | 320 | 464 | 290 | 254 | 263 | 212 | 191 | 190 | 197 |
| Operating income | 3,859 | -539 | -553 | -461 | 8,338 | -406 | -399 | -346 | -268 | -256 | -242 | 45.3 |
| EBIT | 3,859 | -539 | -553 | -461 | 8,338 | -406 | -399 | -346 | -268 | -256 | -242 | 45.3 |
| EBITDA | 3,868 | -529 | -550 | -454 | 8,345 | -401 | -397 | -340 | -261 | -249 | -241 | 49.5 |
| Interest expense | 8.0 | 5.0 | 7.1 | 7.0 | 7.0 | 8.0 | 8.3 | 8.8 | 10.8 | 6.2 | 3.1 | 3.5 |
| Pre-tax income | 4,006 | -394 | -407 | -367 | 8,111 | -336 | -292 | -268 | -294 | -230 | -265 | 72.8 |
| Income tax | 89.0 | 0.0 | -27.4 | 37.5 | 537 | -1.0 | -0.6 | -1.4 | -1.3 | -1.4 | -0.6 | -1.3 |
| Net income | 3,917 | -394 | -379 | -404 | 7,574 | -335 | -291 | -266 | -293 | -229 | -265 | 74.1 |
| Net income to common shareholders | 3,917 | -394 | -379 | -404 | 7,574 | -335 | -291 | -266 | -293 | -229 | -265 | 74.1 |
| Basic EPS | 55.68 | -5.58 | -5.39 | -5.75 | 107.09 | -4.74 | -4.11 | -3.77 | -4.67 | -3.71 | -4.54 | 1.27 |
| Diluted EPS | 55.34 | -5.58 | -5.39 | -5.75 | 105.61 | -4.74 | -4.12 | -3.77 | -4.67 | -3.71 | -4.54 | 1.23 |
| Average shares (basic) | 70.3 | 70.6 | 70.4 | 70.3 | 70.7 | 70.7 | 70.7 | 70.7 | 62.7 | 61.6 | 58.4 | 58.4 |
| Average shares (diluted) | 70.8 | 70.6 | 70.4 | 70.3 | 71.7 | 70.7 | 70.7 | 70.7 | 62.7 | 61.6 | 58.4 | 60.3 |
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 15,949 | 9,506 | 1,980 | 1,540 | 2,068 | 1,762 | 1,600 | 1,230 | 721 | 695 |
| Current assets | 15,670 | 8,528 | 1,780 | 1,316 | 1,722 | 1,420 | 1,427 | 1,179 | 687 | 373 |
| Cash and equivalents | 4,577 | 726 | 449 | 1,069 | 1,129 | 960 | 1,081 | 861 | 589 | 323 |
| Short-term investments | 10,532 | 7,500 | 1,184 | 109 | — | — | 299 | 299 | 75.1 | — |
| Receivables | 320 | 185 | 139 | 137 | 175 | 61.9 | 15.8 | 7.8 | 16.2 | 22.4 |
| Inventory | 0.0 | 10.7 | 7.9 | 1.3 | 118 | 65.0 | — | — | — | — |
| Net property, plant and equipment | 151 | 125 | 150 | 165 | 221 | 213 | 125 | 15.6 | 16.1 | 13.6 |
| Other intangible assets | 45.0 | 12.6 | 12.3 | — | 53.8 | 57.5 | 2.5 | — | — | — |
| Long-term investments | — | 820 | 21.4 | 37.8 | 26.9 | 32.3 | 35.6 | 32.6 | 9.3 | — |
| Current liabilities | 665 | 403 | 285 | 195 | 334 | 355 | 195 | 114 | 73.6 | 87.6 |
| Accounts payable | 257 | 181 | 91.6 | 181 | 266 | 70.4 | 57.5 | 32.7 | 29.4 | 19.7 |
| Long-term debt | 303 | 285 | 0.0 | 401 | 648 | — | — | — | 133 | 329 |
| Total debt | 406 | 392 | 119 | 524 | 787 | 130 | 85.8 | — | 136 | 332 |
| Total liabilities | 1,118 | 889 | 387 | 724 | 1,140 | 533 | 357 | 114 | 207 | 416 |
| Total equity (incl. minority) | 14,831 | 8,617 | 1,593 | 816 | 928 | 1,229 | 1,243 | 1,116 | 515 | 278 |
| Retained earnings | 6.3 | -6,157 | -4,895 | -4,172 | — | -2,290 | -1,444 | -872 | -1,453 | -1,189 |
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 19,762 | 15,301 | 15,949 | 16,797 | 17,180 | 9,122 | 9,506 | 9,630 | 10,156 | 3,587 | 1,980 | 2,176 |
| Current assets | 18,690 | 15,018 | 15,670 | 16,621 | 17,015 | 8,958 | 8,528 | 8,718 | 9,148 | 3,388 | 1,780 | 1,966 |
| Cash and equivalents | 4,038 | 3,849 | 4,577 | 5,973 | 7,244 | 776 | 726 | 511 | 7,155 | 672 | 449 | 384 |
| Short-term investments | 10,419 | 10,619 | 10,532 | 10,197 | 9,334 | — | — | 8.9 | — | 8.9 | — | — |
| Receivables | 3,934 | 239 | 320 | 452 | 427 | 160 | 185 | 166 | 118 | 59.5 | 139 | 373 |
| Inventory | — | — | 0.0 | 0.0 | 10.3 | 254 | 10.7 | 0.8 | 0.8 | 2.9 | 7.9 | 10.7 |
| Net property, plant and equipment | 168 | 164 | 151 | 141 | 134 | 130 | 125 | 129 | 146 | 148 | 150 | 154 |
| Other intangible assets | 839 | 45.0 | 45.0 | 12.7 | 13.6 | 14.1 | 12.6 | 11.6 | 12.0 | 11.6 | 12.3 | 8.8 |
| Long-term investments | — | — | — | — | — | — | 820 | 746 | 837 | 21.7 | 21.4 | 21.0 |
| Current liabilities | 1,337 | 404 | 665 | 1,179 | 1,127 | 357 | 403 | 246 | 257 | 276 | 285 | 258 |
| Accounts payable | 144 | 171 | 257 | 244 | 312 | 244 | 181 | 230 | 227 | 261 | 91.6 | 243 |
| Long-term debt | 312 | 307 | 303 | 298 | 294 | 290 | 285 | 281 | 277 | 273 | — | — |
| Total debt | 411 | 414 | 406 | 406 | 397 | 395 | 392 | 389 | 390 | 389 | — | — |
| Total liabilities | 1,762 | 832 | 1,118 | 1,635 | 1,571 | 814 | 889 | 747 | 760 | 749 | 387 | 359 |
| Total equity (incl. minority) | 18,000 | 14,469 | 14,831 | 15,163 | 15,609 | 8,308 | 8,617 | 8,883 | 9,396 | 2,838 | 1,593 | 1,817 |
| Retained earnings | 3,165 | -356 | 6.3 | 355 | 803 | -6,470 | -6,157 | -5,891 | -5,376 | -5,105 | -4,895 | 1,747 |
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 6,532 | -931 | -426 | -942 | -1,212 | -689 | -409 | -461 | -279 | 40.9 |
| Depreciation and amortization | 24.0 | 23.1 | 20.1 | 102 | 27.8 | 42.7 | 13.7 | 4.5 | 4.8 | 5.4 |
| Capital expenditure | -33.4 | -10.1 | -11.2 | -11.7 | -22.1 | -25.0 | -21.0 | -4.0 | -7.2 | -2.6 |
| Investing cash flow | -2,249 | -7,307 | -1,094 | 281 | -18.1 | -197 | -51.7 | 883 | 221 | -300 |
| Financing cash flow | -378 | 8,288 | 907 | 588 | 1,333 | 761 | 674 | -155 | 338 | 157 |
| Share repurchases | -407 | -352 | -41.6 | 0.0 | -28.6 | — | — | — | — | — |
| Debt issued | 0.0 | 370 | 0.0 | 0.0 | 648 | — | — | — | — | — |
| Debt repaid | -20.2 | -16.4 | -543 | -450 | -14.7 | -29.2 | -8.7 | -158 | -176 | — |
| Effect of exchange rates | -54.7 | 6.2 | -7.2 | 13.7 | 66.2 | 3.7 | 7.1 | 5.9 | -15.1 | 6.4 |
| Net change in cash | 3,851 | 57.4 | -620 | -59.9 | 169 | -121 | 220 | 272 | 265 | -95.5 |
| Free cash flow | 6,499 | -941 | -437 | -954 | -1,234 | — | — | — | — | — |
| Levered free cash flow | 4,392 | -736 | -229 | -384 | -590 | -342 | -318 | 1,059 | -135 | 95.8 |
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 406 | -672 | -1,043 | -444 | 8,520 | -501 | -180 | -295 | -231 | -224 | 59.5 | -113 |
| Depreciation and amortization | 9.0 | 10.0 | 4.6 | 7.2 | 7.0 | 5.0 | 3.5 | 6.2 | 6.8 | 6.6 | 3.5 | 4.2 |
| Capital expenditure | -13.0 | -10.0 | -16.8 | -3.6 | -7.0 | -6.0 | -1.2 | -0.3 | -5.1 | -3.5 | -6.7 | -0.8 |
| Investing cash flow | 223 | -116 | -373 | -855 | -1,575 | 555 | 177 | -6,075 | -30.4 | -1,378 | 6.7 | 160 |
| Financing cash flow | -435 | -8.0 | 10.6 | -78.3 | -310 | -1.0 | -4.6 | -272 | 6,744 | 1,822 | 5.6 | 4.0 |
| Share repurchases | -438 | — | 0.0 | -74.8 | -332 | — | 0.0 | -271 | -81.0 | — | — | — |
| Debt issued | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 370 | — | — |
| Debt repaid | -8.0 | -9.0 | -6.0 | -5.4 | -5.0 | -4.0 | -4.6 | -4.2 | -3.8 | -3.9 | -8.6 | -2.7 |
| Effect of exchange rates | -5.0 | 68.0 | 9.5 | 106 | -167 | -3.0 | 3.6 | -2.0 | 0.9 | 3.6 | -6.9 | 5.3 |
| Net change in cash | 189 | -728 | -1,396 | -1,271 | 6,468 | 50.0 | -4.3 | -6,644 | 6,483 | 223 | 64.9 | 56.8 |
| Free cash flow | 393 | -682 | -1,060 | -447 | 8,513 | -507 | -182 | -296 | -236 | -227 | 52.8 | -114 |
| Levered free cash flow | -346 | -565 | -968 | -258 | 5,952 | -398 | -119 | -236 | -277 | -148 | 118 | -155 |
Financial statements of similar companies
Companies in the group: same industry, similar size
